加载中
NASDAQHealthcareBiotechnology
最新数据
US$0.2724
−US$0.0326 · -10.69%
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
常规交易时段
US$0.2724
−US$0.0326 · -10.69%
盘中时间采用ET。市场数据可能有所延迟。
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
日内区间
当前US$0.2724
52周区间
当前US$0.2724
盘中时间采用ET。市场数据可能有所延迟。
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors. Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy. The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
日内区间
当前US$0.2724
52周区间
当前US$0.2724
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 3185.63万 USD | 2270.13万 USD | 1778.27万 USD | 709.12万 USD | 380.51万 USD |
| 销售、一般及管理费用 | 784.64万 USD | 722.26万 USD | 728.99万 USD | 779万 USD | 363.29万 USD |
| 营业费用 | 3970.26万 USD | 2992.39万 USD | 2507.26万 USD | 1538.12万 USD | 1052.58万 USD |
| 利息收入 | 337.85万 USD | 320万 USD | 116.4万 USD | 54.73万 USD | 64.24 USD |
| 利息支出 | — | — | — | 54.73万 USD | 6.42万 USD |
| 折旧和摊销 | 1.63万 USD | 1.09万 USD | 1.2万 USD | 9268 USD | −308.78万 USD |
| 营业利润 | −3970.26万 USD | −2992.39万 USD | −2507.26万 USD | −1538.12万 USD | −1052.58万 USD |
| 净利润 | −3612.36万 USD | −2672.51万 USD | −2396.42万 USD | −1483.59万 USD | −1045.69万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$5.25
上涨空间 1827.31%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI109.72万0.00%2.3万亿 USD0.03%US$380.8-0.20%
iShares Russell 2000 ETFIWM70.71万0.00%787.4亿 USD0.19%US$276.26-0.59%
iShares Russell 2000 Growth ETFIWO26.58万0.00%139.17亿 USD0.24%US$350.55-0.89%
Vanguard Russell 2000 ETFVTWO21.06万0.00%180亿 USD0.06%US$111.58-0.62%
Vanguard Extended Market ETFVXF20.3万0.00%954亿 USD0.05%US$231.86-0.71%
iShares Micro-Cap ETFIWC9.05万0.01%13.17亿 USD0.60%US$179.91-0.97%
Vanguard Russell 2000 Growth ETFVTWG3.94万0.00%17亿 USD0.06%US$255.95-0.90%
iShares Russell 2500 ETFSMMD1.54万0.00%40.62亿 USD0.23%US$85.665-0.40%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMiShares Russell 2000 Growth ETFIWOVanguard Russell 2000 ETFVTWOVanguard Extended Market ETFVXFiShares Micro-Cap ETFIWCVanguard Russell 2000 Growth ETFVTWGiShares Russell 2500 ETFSMMDAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
